Gilead Buys Myogen To Strengthen Pulmonology Franchise
This article was originally published in The Pink Sheet Daily
Executive Summary
The $2.5 bil. deal will add a late-stage candidate, ambrisentan, for the treatment of pulmonary arterial hypertension to Gilead's pipeline.
You may also be interested in...
Parion Lands Monster Deal With Gilead For Cystic Fibrosis Candidate
With another CF candidate in Phase III, Gilead looks to build a respiratory disease franchise, R&D chief tells “The Pink Sheet” DAILY.
Parion Lands Monster Deal With Gilead For Cystic Fibrosis Candidate
With another CF candidate in Phase III, Gilead looks to build a respiratory disease franchise, R&D chief tells “The Pink Sheet” DAILY.
Gilead Ramps Up For Ambrisentan; Calls For 75 To 100 Sales Reps
Company plans to go toe-to-toe with PAH competitors, CEO tells JP Morgan Healthcare Conference.